Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jitka Malcikova

Showing results (1-10 of 42) with videos related to

Pageof 5
Sort By:
Advances in Experimental Medicine and Biology|September 10, 2013
TP53 aberrations in chronic lymphocytic leukemiaMartin Trbusek, Jitka Malcikova
Leukemia Research|March 8, 2011
Selection of new TP53 mutations by therapy in chronic lymphocytic leukemiaMartin Trbusek, Jitka Malcikova, Jiri Mayer
Frontiers in Oncology|February 27, 2023
Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?Jennifer Edelmann, Jitka Malcikova, John C Riches
Leukemia Research|January 12, 2020
PRIMA-1<sup>MET</sup> cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cellsZuzana Jaskova, Sarka Pavlova, Jitka Malcikova, et al.
Frontiers in Oncology|March 9, 2023
Editorial: Biology and treatment of high-risk CLLEugen Tausch, Jitka Malcikova, John C Riches, et al.
Human Mutation|January 14, 2014
TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemiaJitka Malcikova, Sarka Pavlova, Katerina Stano Kozubik, et al.
Human Mutation|April 27, 2018
Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencingTuomas Tikkanen, Bernard Leroy, Jean Louis Fournier, et al.
Biological Chemistry|February 5, 2010
Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activationJitka Malcikova, Boris Tichy, Jiri Damborsky, et al.
Oncotarget|October 21, 2017
Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizonsAna E Rodríguez-Vicente, Vasilis Bikos, María Hernández-Sánchez, et al.
International Journal of Oncology|February 4, 2010
Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphomaLenka Stefancikova, Mojmir Moulis, Pavel Fabian, et al.
Pageof 5

Showing results (1-10 of 42) with videos related to

Sort By:
Pageof 5
Advances in Experimental Medicine and Biology|September 10, 2013
TP53 aberrations in chronic lymphocytic leukemiaMartin Trbusek, Jitka Malcikova
Leukemia Research|March 8, 2011
Selection of new TP53 mutations by therapy in chronic lymphocytic leukemiaMartin Trbusek, Jitka Malcikova, Jiri Mayer
Frontiers in Oncology|February 27, 2023
Opinion: What defines high-risk CLL in the post-chemoimmunotherapy era?Jennifer Edelmann, Jitka Malcikova, John C Riches
Leukemia Research|January 12, 2020
PRIMA-1<sup>MET</sup> cytotoxic effect correlates with p53 protein reduction in TP53-mutated chronic lymphocytic leukemia cellsZuzana Jaskova, Sarka Pavlova, Jitka Malcikova, et al.
Frontiers in Oncology|March 9, 2023
Editorial: Biology and treatment of high-risk CLLEugen Tausch, Jitka Malcikova, John C Riches, et al.
Human Mutation|January 14, 2014
TP53 mutation analysis in clinical practice: lessons from chronic lymphocytic leukemiaJitka Malcikova, Sarka Pavlova, Katerina Stano Kozubik, et al.
Human Mutation|April 27, 2018
Seshat: A Web service for accurate annotation, validation, and analysis of TP53 variants generated by conventional and next-generation sequencingTuomas Tikkanen, Bernard Leroy, Jean Louis Fournier, et al.
Biological Chemistry|February 5, 2010
Analysis of the DNA-binding activity of p53 mutants using functional protein microarrays and its relationship to transcriptional activationJitka Malcikova, Boris Tichy, Jiri Damborsky, et al.
Oncotarget|October 21, 2017
Next-generation sequencing in chronic lymphocytic leukemia: recent findings and new horizonsAna E Rodríguez-Vicente, Vasilis Bikos, María Hernández-Sánchez, et al.
International Journal of Oncology|February 4, 2010
Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphomaLenka Stefancikova, Mojmir Moulis, Pavel Fabian, et al.
Pageof 5